Product Description
AstraZeneca is developing TACE (transarterial chemoembolization) as a transarterial therapy procedure for the treatment of hepatocellular carcinoma (HCC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03778957)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Ecuador | India | Ireland | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 23
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Liver Cancer|Melanoma|Neuroendocrine Tumors|Primitive Neuroectodermal Tumors
Phase 2: Cholangiocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IDADOX | P2 |
Recruiting |
Hepatocellular Carcinoma|Liver Cancer |
2025-12-31 |
12% |
2025-01-08 |
Primary Completion Date|Primary Endpoints |
| AK104-308 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-10-25 |
32% |
2025-03-13 |
Primary Endpoints |
| HX008-Ⅲ-MM-01 | P3 |
Not yet recruiting |
Primitive Neuroectodermal Tumors|Neuroendocrine Tumors|Melanoma |
2024-12-30 |
60% |
2022-12-14 |
Primary Endpoints|Treatments |
| CCGLC-012 | P2 |
Recruiting |
Cholangiocarcinoma |
2025-01-31 |
37% |
2024-03-27 |
Primary Endpoints|Treatments |
| 23-OBU-FJ-HCC-II-012 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-11-15 |
42% |
2024-02-29 |
Primary Endpoints|Treatments|Trial Status |
| PRO00028690 | P2 |
Enrolling by invitation |
Hepatocellular Carcinoma |
2026-06-30 |
63% |
2022-09-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
| UCI 19-49 [HS# 2020-5807] | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-06-01 |
12% |
2024-03-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| UPCC 01215 | P2 |
Completed |
Neuroendocrine Tumors |
2024-04-30 |
19% |
2025-01-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| AK104-216 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-08-15 |
12% |
2025-03-13 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
| PETAL | P2 |
Completed |
Hepatocellular Carcinoma |
2023-02-01 |
12% |
2025-02-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| JapicCTI-205286 | P3 |
Active |
Hepatocellular Carcinoma |
2029-12-31 |
|||
| jRCT2080225190 | P3 |
Completed |
Hepatocellular Carcinoma |
2029-12-31 |
|||
| ML42612 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2029-02-01 |
94% |
2025-02-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| LEAP-012 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2028-06-30 |
61% |
2023-02-03 |
Primary Endpoints|Trial Status |
| SHR-1210-â ¢-336 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-07-30 |
39% |
2025-02-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |
| EMERALD-3 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-12-31 |
70% |
2025-01-16 |
|
| 2022-SR-558 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2025-11-01 |
12% |
2025-01-03 |
|
| CheckMate 74W | P3 |
Completed |
Liver Cancer |
2023-12-12 |
91% |
2024-11-27 |
|
| NCT03143270 | P1 |
Active, not recruiting |
Liver Cancer |
2026-04-01 |
23% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| EMERALD-1 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-09-11 |
95% |
2024-01-18 |
Primary Endpoints|Study Completion Date|Treatments |
| JS014-F01 | P1 |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-01-01 |
2025-03-20 |
Primary Endpoints|Treatments |
|
| ZS-IR-2019B | P1 |
Active, not recruiting |
Hepatocellular Carcinoma |
2024-10-30 |
21% |
2024-08-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
| CISLD-13 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2027-04-01 |
12% |
2025-05-31 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/21/2025 |
News Article |
AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer |
|
02/24/2025 |
News Article |
Cambium Secures $18.5 Million Series A, Expands into Mass Timber to Accelerate Sustainable Materials for the Built Environment |
|
10/31/2024 |
News Article |
Merck Announces Third-Quarter 2024 Financial Results |
|
09/05/2024 |
News Article |
Eisai Accelerates Progress In Oncology Research With New Data At Esmo Congress 2024 |